TECHBio-Techne

Healthcare

$72.47+37% 1Y

$72.47

$43.2252 weeks$72.62

Is it safe?

Good

Strong, no red flags: a safe balance sheet, clean books, and quality strong.

4 good, 1 neutral, 1 without data

SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Honest booksLow risk

Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Quality7 / 9

High fundamental quality Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Credit gradeAAderived · Jun 30, 2026

Net cash and profitable. A rule of thumb on leverage, not a credit rating.

Drawdown risk45% volderived · Oct 9, 2026

Moderate price swings, typical volatility. Worst drawdown -67% · now at/near its 52-week high.

Unless marked, from SEC EDGAR, as of Jun 30, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitymiddle of the market

Max drawdownmiddle of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can TECH take a bad year?

Bio-Techne holds $65M more cash than debt, so a bad year is a question about profits, not about lenders.

$65M

Net cash

Net debt / EBITDA: net cash
Net debt / EBITDA · no net borrowings to measure against earnings
Altman Z-score: 10.04
Altman Z-score · safe zone, above 3
Interest cover: 26.2×
Interest cover · operating profit covers the interest bill several times over